LIVMARLI

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Romania.

Active ingredients

The drug LIVMARLI contains one active pharmaceutical ingredient (API):

1	Maralixibat UNII V78M04F0XC - MARALIXIBAT CHLORIDE
	Maralixibat is a minimally absorbed, reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). Maralixibat acts locally in the distal ileum to decrease the reuptake of bile acids and increase the clearance of bile acids through the colon, reducing the concentration of bile acids in the serum.
	Read more about Maralixibat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LIVMARLI Oral solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A05AX04		A Alimentary tract and metabolism → A05 Bile and liver therapy → A05A Bile therapy → A05AX Other drugs for bile therapy
Discover more medicines within A05AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3038587
FR	Base de données publique des médicaments	61952616
IL	מִשְׂרַד הַבְּרִיאוּת	9219
IT	Agenzia del Farmaco	050418019
LT	Valstybinė vaistų kontrolės tarnyba	1096065
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69366001
US	FDA, National Drug Code	79378-110